Zanzalintinib (NCT06794229)

Name: Zanzalintinib trial for Locally Advanced Renal Cell Carcinoma (NCT06794229)
Uploaded: 2026-10-31T19:21:02.239Z
Duration: 1 min 11 s
Description: Zanzalintinib trial for Locally Advanced Renal Cell Carcinoma (NCT06794229). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06794229.

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis: a one-minute explainerNCT067942291 min

Zanzalintinib trial for Locally Advanced Renal Cell Carcinoma (NCT06794229). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated clear-cell kidney cancer that is locally advanced or surgically difficult. Only small, nonmeasurable metastases are allowed.

The idea: oral zanzalintinib blocks growth signals; intravenous nivolumab releases an immune brake. After 12 weeks, operable tumors undergo surgery. Patients with stable or shrinking tumors still unsuitable for surgery may continue treatment, up to 48 weeks total. Progression ends study treatment.

This phase 2 study plans 69 patients. Qian Qin leads; three US sites are recruiting.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.